Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
Profound Medical Corp. (NASDAQ: PROF) will announce its Q3 2022 financial results on November 3, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET to review the results and discuss business developments. The company specializes in customizable, incision-free therapies for tissue ablation, notably its TULSA-PRO® and Sonalleve® technologies, which have received various regulatory approvals. These innovations target conditions such as prostate cancer and uterine fibroids.
- TULSA-PRO® and Sonalleve® technologies have received CE marking, FDA clearance, and Health Canada approval.
- TULSA-PRO® has potential applications in various stages of prostate cancer and benign prostatic hyperplasia.
- None.
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
| Third Quarter 2022 Results Conference Call Details: | |
| Date: | Thursday, November 3, 2022 |
| Time: | 4:30 p.m. ET |
| Live Call Registration: | https://register.vevent.com/register/BI9fe61ff681a946ce83ad793a7ce94310 |
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical announce its Q3 2022 financial results?
What time is Profound Medical's Q3 2022 results conference call?
What technologies does Profound Medical specialize in?
What approvals have the TULSA-PRO® and Sonalleve® technologies received?
